Stockholders Approve 1-for-100 Reverse Stock Split and Viskase Merger Agreement

summarizeSummary

Enzon Pharmaceuticals announced that its stockholders have approved a 1-for-100 reverse stock split and the previously disclosed merger agreement with Viskase Companies, Inc. via a consent solicitation.

check_boxKey Events

• Reverse Stock Split Approved

  Stockholders approved an amendment to the Company's charter to effect a 1-for-100 reverse stock split, with 55.2% of outstanding shares consenting.

• Merger Agreement with Viskase Approved

  The Agreement and Plan of Merger with Viskase Companies, Inc. was approved by stockholders, with 57.1% of outstanding shares consenting.

• Consent Solicitation Concluded

  The consent solicitation, which sought approval for both the reverse stock split and the merger, concluded on February 11, 2026, after receiving the requisite number of consents.

• Follows Prior Merger Disclosures

  This approval follows a series of recent filings, including an S-4 and 424B3 on January 28 and January 30, 2026, which detailed the merger terms and reverse stock split proposal.

auto_awesomeAnalysis

This filing marks a critical development for Enzon Pharmaceuticals, confirming stockholder approval for both a significant 1-for-100 reverse stock split and the merger agreement with Viskase Companies, Inc. For a company with a market capitalization under $5 million, these approvals are thesis-altering. The reverse stock split, while intended to increase share price, often signals financial distress and can be a precursor to delisting if not successful. The merger approval, following a series of related filings since late January, provides a definitive path forward for the company, albeit one that involves substantial corporate restructuring. Investors should monitor the execution of these plans and the combined entity's performance post-merger, especially given the prior disclosures of potential dilution.